MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said it has appointed Yifat Steuer as its new chief operating officer and deputy chief executive officer.
Steuer, a qualified chartered accountant, has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline, as well as with SMEs and start-ups, the bio-pharma company said in a statement.
She will work closely with company CEO Roby Zomer to execute on MGC Pharma's business strategy, utilising her experience in in pharmaceuticals, manufacturing, logistics, medical technology and digital health.
Additionally, MGC Pharma announced the formal appointment of UK capital markets advisor Hannam & Partners as financial and corporate advisors to the company with immediate effect
Hannam & Partners is "a highly regarded UK advisory firm with a long track record in UK capital markets" and more recently in the UK and EU cannabis sector, it noted.
MGC Pharma also said the role of chairman Brett Mitchell has changed from an executive to a non-executive position, in line with the corporate structure of UK listed companies.
The company said it is holding an investor update on 11 October following the publication of its 2022 annual report.